Caribou Biosciences Valuation Multiples

Caribou Biosciences Overview

About Caribou Biosciences

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Founded

2011

HQ

Employees

147

Website

cariboubio.com

Sectors

BiopharmaceuticalsBioTechDeepTech

Financials (LTM)

Revenue: $14M

EBITDA: ($141M)

EV

$38M

Valuation Multiples

Multiples.vc

Start free trial

Caribou Biosciences Financials

Caribou Biosciences reported last 12-month revenue of $14M and negative EBITDA of ($141M).

In the same LTM period, Caribou Biosciences generated $14M in gross profit, ($141M) in EBITDA losses, and had net loss of ($144M).

Caribou Biosciences P&L

In the most recent fiscal year, Caribou Biosciences reported revenue of $11M and EBITDA of ($133M).

Caribou Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

Caribou Biosciences Stock Performance

Caribou Biosciences has current market cap of $160M, and enterprise value of $38M.

Caribou Biosciences' stock price is $1.71.

Caribou Biosciences Valuation Multiples

Caribou Biosciences trades at 2.7x EV/Revenue multiple, and (0.3x) EV/EBITDA.

Caribou Biosciences Financial Valuation Multiples

As of March 31, 2026, Caribou Biosciences has market cap of $160M and EV of $38M.

Equity research analysts estimate Caribou Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Caribou Biosciences has a P/E ratio of (1.1x).

Caribou Biosciences Margins & Growth Rates

Caribou Biosciences' revenue in the last 12 month grew by 65%.

Caribou Biosciences' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.0M for the same period.

Caribou Biosciences' rule of 40 is (661%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Caribou Biosciences' rule of X is (513%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Caribou Biosciences Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Caribou Biosciences M&A Activity

Caribou Biosciences acquired XXX companies to date.

Last acquisition by Caribou Biosciences was on XXXXXXXX, XXXXX. Caribou Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Caribou Biosciences Investment Activity

Caribou Biosciences invested in XXX companies to date.

Caribou Biosciences made its latest investment on XXXXXXXX, XXXXX. Caribou Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).